Baxter Japan Files Additional Application For Feiba To Prevent Bleeding
This article was originally published in PharmAsia News
Executive Summary
Baxter Japan filed an application June 28 to use Feiba injection, a drug used in the treatment of bleeding in hemophilia when the effect of coagulation factor agents is weak, in regularly administered treatment to prevent bleeding.